Cisplatin remains a major antineoplastic drug for the treatment of solid tumors. Its chief dose-
limiting side effect is nephrotoxicity, which evolves slowly and predictably after initial and
repeated exposure. The kidney accumulates cisplatin to a higher degree than other organs
perhaps via mediated transport. Functionally, reduced renal perfusion and a concentrating
defect characterize its nephrotoxicity, whereas morphologically necrosis of the terminal
portion of the proximal tubule and apoptosis predominantly in the distal nephron …